An interventional study of An implementation model for co-located Medications for Opioid Use Disorder (MOUD) prescription in the NICU in Opioid Use Disorder and Neonatal Abstinence Syndrome, sponsored by University of Pennsylvania. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by University of Pennsylvania · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Opioid-Related Disorders by University of Pennsylvania — 9 open to participants now, 11 under way, none of them phase 3. Opioid-Related Disorders · University of Pennsylvania.
Among the 35 studies in Opioid-Related Disorders by University of Pennsylvania, this one is the 20th largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2024, is one of 15 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 30th registered.
1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
Browse Opioid-Related Disorders studies →9 of the 35 studies in Opioid-Related Disorders by University of Pennsylvania are open now, in 1 country. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Women only
University of Pennsylvania · Sites in United States
Ages 18–60
University of Pennsylvania · Sites in United States
Ages 18–60 · Healthy volunteers
University of Pennsylvania · Sites in United States
Ages 18+
University of Pennsylvania · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 7 · Phase 4 3
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 63 across 1,167 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 61 across the 33 interventional studies, 145 across the 2 observational. Of the 22 that completed or were terminated, 9 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 234 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 110 (70%) have results posted.
9 of the studies in Opioid-Related Disorders by University of Pennsylvania that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06379984University of PennsylvaniaRapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use | 2026-12-31 |
| NCT06643988University of PennsylvaniaAutobiographical Memory in Opioid Use Disorder | 2027-01 |
| NCT06136247University of PennsylvaniaIntegrating Brain, Neurocognitive, and Computational Tools in OUD | 2027-01-31 |
| NCT06843213University of PennsylvaniaTeaching Health Resilience in a Hospital Setting: A Peer-led Intervention | 2027-03-31 |
| NCT06810310University of PennsylvaniaPsilocybin on Brain Mechanisms of Motivation in OUD | 2027-05-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 35 studies in Opioid-Related Disorders by University of Pennsylvania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to address the gap in maternal OUD treatment and infant neonatal opioid withdrawal syndrome care. The research team will develop a treatment model and a set of strategies to provide evidence-based OUD treatment to postpartum mothers in NICUs.
First, the investigators will conduct a needs assessment via in-depth qualitative interviews with NICU mothers and clinicians. Then, with the expertise of the advisory board, the the researchers will create a protocol for implementing maternal OUD treatment at the NICU bedside. The researchers will then implement the protocol in two partner NICUs and evaluate the acceptability and feasibility to patients, providers, and clinical, and administrative leaders.
The goal of this research study is to integrate maternal mental health and substance abuse treatment in pediatric settings and to refine, test, and examine the acceptability and feasibility of applying the adapted model.
The increasing prevalence of pregnant and postpartum women affected by Opioid Use Disorder (OUD) in the US is highlighted by the growing number of babies referred to the NICU for Neonatal Abstinence Syndrome after birth. Despite recent advances in integrating mental health and substance abuse treatment into adult healthcare settings, no current treatment options exist to integrate maternal OUD treatment and referrals into the pediatric care setting making it unlikely that mothers will be able to access care. In order to preserve the dyadic bond, improve maternal functioning, and provide a more stable environment for the infant after discharge from the NICU, the researchers now embark on a study utilizing steps from intervention mapping to identify facilitators and barriers to integrated maternal OUD treatment and referral in the NICU, adapt existing evidence-based models of co-located OUD care to the NICU setting, and test the feasibility and acceptability of the new model. In Aim 1, the researchers will collect qualitative data via in-depth interviews with 32 NICU providers, social workers, administrators, and parents to determine barriers and facilitators to offering bedside buprenorphine induction and treatment. In Aim 2, the researchers will convene an advisory board to review data collected in Aim 1 and to develop a plan for implementing buprenorphine initiation into the study's unique setting to address the issue- the provision of adult focused OUD care in a pediatric care setting. Aim 2 does not constitute Human Subjects research. The primary outcome of Aim 2 will be a suite of implementation strategies to pilot test in Aim 3. Aim 3 is a pilot case series implementation trial where the researchers will test the adapted intervention to determine feasibility and acceptability to both providers and patients. As this is a case series the investigators propose to recruit 10 participants from each of the two partner NICUs for a total enrollment of N= 20 in Aim 3. A formal sample size calculation was not performed as there is no data on which to a base a formal sample size calculation. For pilot studies with an expected medium standardized effect size, a case number of N= 15 per group has been recommended for pilot studies preceding a possible main study with a power of 90%. The investigators plan to recruit 20 participants to account for possible attrition. The researchers are not necessarily powered to detect an effect. Participants will not be randomized to condition; all NICU mothers meeting inclusion criteria during the study timeline for Aim 3 will be invited to participate in Aim 3. The outcomes of acceptability and feasibility will be measured through questionnaires, interviews, and treatment initiation and retention statistics.
Inclusion Criteria for Interview Participants in Aim 1:
Inclusion Criteria for Mothers in Aim 1:
Inclusion Criteria for Clinicians in Aim 3:
Inclusion Criteria for Mothers in Aim 3:
Exclusion Criteria for Interview Participants in Aim 1:
- None
Exclusion Criteria for Mothers in Aim 1:
- None
Exclusion Criteria for Clinicians in Aim 3:
- None
Exclusion Criteria for Mothers in Aim 3:
- Active suicidal ideation, or other severe psychopathology that must be addressed before effective MOUD can be prescribed
In Aim 3, all recruited participants will receive the intervention.
Behavioral: An implementation model for co-located Medications for Opioid Use Disorder (MOUD) prescription in the NICU
We will use implementation mapping to develop a suite of implementation strategies to deliver evidence-based MOUD prescription to mothers attending the bedside of their infants hospitalized in the NICU. The intervention itself is buprenorphine induction and treatment, however the model for delivery is not yet developed, consistent with the need for results from Aim 1 to inform the approach used to develop the implementation model in Aim 2.
Qualitative Interview for NICU Providers
In-depth qualitative interview focused on providers' attitudes and knowledge about barriers and facilitators of buprenorphine induction for mothers in the NICU. This interview will be guided by the Consolidated Framework for Implementation Research to query about barriers and facilitators of MOUD provision in the NICU, with the primary goal of identifying contextual determinants of co-located care.
Time frame: Time 1 (baseline)
Qualitative Interview for Parents
In-dept qualitative interview focused on mothers' attitudes about receiving MOUD in the NICU while caring for their hospitalized infant. This interview will be guided by the Consolidated Framework for Implementation Research to query about what would make this more attractive, feasible, and engagement more likely.
Time frame: Time 1 (baseline)
Feasibility of Intervention Measure
A 4-item,psychometrically-validated measure that indexes the extent to which stakeholders perceive an implementation strategy is feasible.
Time frame: Up to 9 months
Acceptability of Intervention Measure
A 4-item,psychometrically-validated measure that indexes the extent to which stakeholders perceive an implementation strategy is acceptable.
Time frame: Up to 9 months
Recruitment and Retention Statistics
The proportion of mothers of babies in the NICU who agree to receive MOUD in the NICU (Time 2; T2), who remain in care for the duration of their baby's stay (Time 3; T3), and length of time they remain in outpatient treatment after treatment (Time 4; T4).
Time frame: Up to 1 year.
Demographics survey
Brief questionnaire about provider and parent demographic (e.g., age, gender) and professional characteristics (e.g., provider role, years of experience, level of training), and work setting
Time frame: Time 1 (baseline)
Plan to share: No
Started Jul 2024 (actual). Primary completion is estimated for May 2027, 34 months after the start.
Of 464 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 34 months is above that.
Counting every sponsor, half of 495 studies reached it within 29 months; a quarter within 13 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.